MW
Therapeutic Areas
Thrombolytic Science International Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dual Thrombolytic Regimen (tPA + HisproUK) | Ischemic Stroke | Phase 2 |
| Mutant Prourokinase (HisproUK) | Not Specified (IND Cleared) | IND Cleared |
Leadership Team at Thrombolytic Science International
AW
Alexis Wallace
Chief Executive Officer, Co-founder & Board Member
VG
Victor Gurewich, MD
Chief Scientific Officer, Co-founder & Board Member
JF
Judith Feher Gurewich, PhD
Executive Chair of the Board
KO
Kemal Oğuz Kalafat, MD, MHA
Board Member
ÖT
Öner Tulum, PhD, MBA, MA
Board Member